Methodology and Early Results of the First Surveillance Program on Prevention and Control of Antimicrobial Resistance in Isfahan, Iran: The IAS-I Study.
Bacteria
Iran
drug resistance
epidemiology
methods
Journal
International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
05
2019
accepted:
14
10
2019
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
23
10
2020
Statut:
epublish
Résumé
Isfahan Antibiotic Resistance Surveillance System-1 has been instituted in Isfahan, Iran to construct a project for surveillance of clinically significant bacteria, and to help raise a logic regional stewardship program for prevention and control of disseminating-resistant organisms. During March 2016 to March 2018, an antibiotic resistance surveillance system was designed and implemented by Isfahan Infectious Diseases and Tropical Medicine Research Center. The surveillance program was implemented in three general hospitals in Isfahan. In addition to the routine microbiology data, clinical data (differentiation between true infections and contamination, healthcare-associated infections (HCAI) and community-acquired infections (CAI), as well as determination of the infection site) were obtained and analyzed by WHONET software. During a 2-year period, from 7056 samples that revealed growth of bacteria, 3632 (51.5%) isolates were detected as contamination and 3424 (48.5%) true bacterial isolates were identified. Of these, about 32% of isolates were recognized as HCAI. Totally, the most recognized infections were urinary tract infection, bloodstream infection and skin and soft tissue infections. In patients with HCAIs, 70% of isolates were gram negative and in patients with CAIs 73% isolates were gram negative bacteria. The strength of the project is gathering enough clinical information in addition to microbiologic data, which would increase application of the results for empiric treatment and prevention of the infectious diseases in clinical settings.
Sections du résumé
BACKGROUND
BACKGROUND
Isfahan Antibiotic Resistance Surveillance System-1 has been instituted in Isfahan, Iran to construct a project for surveillance of clinically significant bacteria, and to help raise a logic regional stewardship program for prevention and control of disseminating-resistant organisms.
METHODS
METHODS
During March 2016 to March 2018, an antibiotic resistance surveillance system was designed and implemented by Isfahan Infectious Diseases and Tropical Medicine Research Center. The surveillance program was implemented in three general hospitals in Isfahan. In addition to the routine microbiology data, clinical data (differentiation between true infections and contamination, healthcare-associated infections (HCAI) and community-acquired infections (CAI), as well as determination of the infection site) were obtained and analyzed by WHONET software.
RESULTS
RESULTS
During a 2-year period, from 7056 samples that revealed growth of bacteria, 3632 (51.5%) isolates were detected as contamination and 3424 (48.5%) true bacterial isolates were identified. Of these, about 32% of isolates were recognized as HCAI. Totally, the most recognized infections were urinary tract infection, bloodstream infection and skin and soft tissue infections. In patients with HCAIs, 70% of isolates were gram negative and in patients with CAIs 73% isolates were gram negative bacteria.
CONCLUSIONS
CONCLUSIONS
The strength of the project is gathering enough clinical information in addition to microbiologic data, which would increase application of the results for empiric treatment and prevention of the infectious diseases in clinical settings.
Identifiants
pubmed: 33088465
doi: 10.4103/ijpvm.IJPVM_189_19
pii: IJPVM-11-137
pmc: PMC7554560
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137Informations de copyright
Copyright: © 2020 International Journal of Preventive Medicine.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Iran J Basic Med Sci. 2015 Jan;18(1):2-7
pubmed: 25810869
J Glob Antimicrob Resist. 2018 Mar;12:96-103
pubmed: 28941791
Emerg Infect Dis. 2014 Mar;20(3):434-41
pubmed: 24564906
J Glob Antimicrob Resist. 2017 Jun;9:3-7
pubmed: 28232229
Iran J Public Health. 2018 Jan;47(1):1-12
pubmed: 29318111
Int J Infect Dis. 1999 Spring;3(3):153-6
pubmed: 10460927
Clin Microbiol Rev. 2006 Oct;19(4):788-802
pubmed: 17041144
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Med J Islam Repub Iran. 2016 Oct 17;30:428
pubmed: 28210593
Int J Antimicrob Agents. 2000 Jul;15(2):91-101
pubmed: 10854804
Iran J Public Health. 2018 Mar;47(3):317-326
pubmed: 29845018
Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1387-92
pubmed: 27344575
Clin Microbiol Infect. 2001 Jun;7(6):316-25
pubmed: 11442565
J Microbiol Immunol Infect. 2007 Oct;40(5):438-44
pubmed: 17932605